SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Raffi F)
 

Search: WFRF:(Raffi F) > Blood Telomere Leng...

  • Stella-Ascariz, N. (author)

Blood Telomere Length Changes after Ritonavir-Boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-07-03
  • Oxford University Press (OUP),2018

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/273196
  • https://gup.ub.gu.se/publication/273196URI
  • https://doi.org/10.1093/infdis/jiy399DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background. Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. Methods. NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression. Results. At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C. Conclusion. Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Montejano, R. (author)
  • Rodriguez-Centeno, J. (author)
  • Alejos, B. (author)
  • Schwimmer, C. (author)
  • Bernardino, J. I. (author)
  • Rodes, B. (author)
  • Allavena, C. (author)
  • Hoffmann, C. (author)
  • Gisslén, Magnus,1962Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xgissm (author)
  • De Miguel, R. (author)
  • Esteban-Cantos, A. (author)
  • Wallet, C. (author)
  • Raffi, F. (author)
  • Arribas, J. R. (author)
  • Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar (creator_code:org_t)

Related titles

  • In:Journal of Infectious Diseases: Oxford University Press (OUP)218:10, s. 1523-15300022-18991537-6613

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view